Arcus Biosciences

biopharmaceutical company

RCUS NYSE SEC CIK 1724521
Follow Arcus Biosciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $3M −50% vs same quarter last year
Net income −$128M +5.2% vs same quarter last year
EPS, diluted −$1.00 +21.3% vs same quarter last year
Operating cash flow −$88M +9.3% vs same quarter last year
Revenue by quarter
$23M
$8M
$8M
$6M
$11M
$7M
$33M
$3M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income11 fiscal years
  • Revenue
  • Net income
−$400M−$200M$0$200M$400MFY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$33M−$353M
FY24$51M−$283M
FY23$37M−$307M
FY22$38M−$267M
FY21$383M$53M
FY20$78M−$123M
FY19$15M−$84.7M
FY18$8.4M−$49.6M
FY17$1.4M−$53.1M
FY16-−$18M
FY15--
MarginsShare of revenue
  • Operating margin
  • Net margin
−4000%−3000%−2000%−1000%0%1000%FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−1169.7%−1069.7%
FY24−647.1%−554.9%
FY23−918.9%−829.7%
FY22−736.8%−702.6%
FY2114.1%13.8%
FY20−159%−157.7%
FY19−591.4%−564.7%
FY18−656.8%−593.7%
FY17−3782.1%−3756.7%
FY16--
FY15--
Free cash flowOperating cash flow minus capital expenditure
−$500M−$250M$0$250M$500MFY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$484M
FY24−$176M
FY23−$330M
FY22$432M
FY21−$282M
FY20$108M
FY19−$75.4M
FY18−$46.7M
FY17−$30.6M
FY16−$17M
FY15-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Arcus Biosciences
  • Healthcare median
−4000%−3000%−2000%−1000%0%1000%FY15FY17FY19FY21FY23FY25
Show the numbers
YearArcus BiosciencesHealthcare median
FY25−1069.7%−30.6%
FY24−554.9%−47%
FY23−829.7%−58%
FY22−702.6%−80.4%
FY2113.8%−71.8%
FY20−157.7%−62.2%
FY19−564.7%−46.2%
FY18−593.7%−49.6%
FY17−3756.7%−45.9%
FY16-−36%
FY15-−37.8%